Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report)’s stock price traded up 10% on Thursday . The company traded as high as $14.17 and last traded at $14.3010. 622,068 shares changed hands during trading, a decline of 35% from the average session volume of 959,875 shares. The stock had previously closed at $13.00.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on VOR shares. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Monday, June 1st. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.25.
Get Our Latest Stock Analysis on VOR
Vor Biopharma Trading Up 10.6%
Vor Biopharma (NASDAQ:VOR – Get Free Report) last issued its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. As a group, research analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current year.
Insider Activity at Vor Biopharma
In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the transaction, the director directly owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 3,002,903 shares of company stock valued at $49,412,176 in the last three months. Corporate insiders own 0.27% of the company’s stock.
Hedge Funds Weigh In On Vor Biopharma
Several institutional investors have recently modified their holdings of VOR. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma during the fourth quarter worth $36,000. Squarepoint Ops LLC bought a new position in Vor Biopharma in the 3rd quarter valued at $230,000. Bank of America Corp DE increased its position in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Vor Biopharma in the 3rd quarter worth about $304,000. 97.29% of the stock is owned by institutional investors.
About Vor Biopharma
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Read More
- Five stocks we like better than Vor Biopharma
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
